Subtype-specific Clinical Presentation, Medical Treatment and Family Impact of Influenza in Children 1-5 Years of Age Treated in Outpatient Practices in Germany During Three Postpandemic Years, 2013-2015.
Identifieur interne : 000033 ( Main/Exploration ); précédent : 000032; suivant : 000034Subtype-specific Clinical Presentation, Medical Treatment and Family Impact of Influenza in Children 1-5 Years of Age Treated in Outpatient Practices in Germany During Three Postpandemic Years, 2013-2015.
Auteurs : Andrea Streng [Allemagne] ; Christiane Prifert [Allemagne] ; Benedikt Weissbrich [Allemagne] ; Andreas Sauerbrei [Allemagne] ; Ruprecht Schmidt-Ott [Belgique] ; Johannes G. Liese [Allemagne]Source :
- The Pediatric infectious disease journal [ 1532-0987 ] ; 2018.
Descripteurs français
- KwdFr :
- Allemagne (épidémiologie), Antiviraux (usage thérapeutique), Bronchite (traitement médicamenteux), Bronchite (virologie), Enfant d'âge préscolaire, Femelle, Fièvre, Grippe humaine (traitement médicamenteux), Humains, Infections de l'appareil respiratoire (traitement médicamenteux), Infections de l'appareil respiratoire (virologie), Mâle, Nourrisson, Oséltamivir (usage thérapeutique), Pandémies, Patients en consultation externe (), Pharyngite (traitement médicamenteux), Pharyngite (épidémiologie), Réaction de polymérisation en chaine multiplex, Saisons, Sous-type H1N1 du virus de la grippe A (isolement et purification), Sous-type H3N2 du virus de la grippe A (isolement et purification), Virus influenza B (isolement et purification), Épidémiosurveillance, Études prospectives.
- MESH :
- isolement et purification : Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A, Virus influenza B.
- traitement médicamenteux : Bronchite, Grippe humaine, Infections de l'appareil respiratoire, Pharyngite.
- usage thérapeutique : Antiviraux, Oséltamivir.
- virologie : Bronchite, Infections de l'appareil respiratoire.
- épidémiologie : Allemagne, Pharyngite.
- Enfant d'âge préscolaire, Femelle, Fièvre, Humains, Mâle, Nourrisson, Pandémies, Patients en consultation externe, Réaction de polymérisation en chaine multiplex, Saisons, Épidémiosurveillance, Études prospectives.
- Wicri :
- geographic : Allemagne.
English descriptors
- KwdEn :
- Antiviral Agents (therapeutic use), Bronchitis (drug therapy), Bronchitis (virology), Child, Preschool, Epidemiological Monitoring, Female, Fever, Germany (epidemiology), Humans, Infant, Influenza A Virus, H1N1 Subtype (isolation & purification), Influenza A Virus, H3N2 Subtype (isolation & purification), Influenza B virus (isolation & purification), Influenza, Human (drug therapy), Male, Multiplex Polymerase Chain Reaction, Oseltamivir (therapeutic use), Outpatients (statistics & numerical data), Pandemics, Pharyngitis (drug therapy), Pharyngitis (epidemiology), Prospective Studies, Respiratory Tract Infections (drug therapy), Respiratory Tract Infections (virology), Seasons.
- MESH :
- chemical , therapeutic use : Antiviral Agents, Oseltamivir.
- geographic , epidemiology : Germany.
- drug therapy : Bronchitis, Influenza, Human, Pharyngitis, Respiratory Tract Infections.
- epidemiology : Pharyngitis.
- isolation & purification : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza B virus.
- statistics & numerical data : Outpatients.
- virology : Bronchitis, Respiratory Tract Infections.
- Child, Preschool, Epidemiological Monitoring, Female, Fever, Humans, Infant, Male, Multiplex Polymerase Chain Reaction, Pandemics, Prospective Studies, Seasons.
Abstract
BACKGROUND
Limited data on the influenza burden in pediatric outpatients are available, especially regarding direct comparison of the cocirculating (sub)types A(H1N1)pdm09, A(H3N2) and B.
METHODS
Children 1-5 years of age, unvaccinated against influenza and presenting with febrile acute respiratory infections (ARIs), were enrolled in 33 pediatric practices in Germany from 2013 to 2015 (January-May). Influenza was confirmed by multiplex polymerase chain reaction from pharyngeal swabs and (sub)typed.
RESULTS
In 805 children with ARI, influenza was the most frequently detected respiratory virus (n = 305; 37.9%). Of 217 influenza patients included, 122 (56.2%) were infected with A(H3N2), 56 (25.8%) with A(H1N1)pdm09 and 39 (18.0%) with B. Median age was 3.7 years [interquartile range (IQR), 2.1-4.8]; 11% had underlying conditions. Median fever duration was 4 days (IQR, 3-5), and the disease duration was 9 days (IQR, 7-12). Most frequent diagnoses were pharyngitis (26%), bronchitis (18%) and acute otitis media (10%). Children received mainly antipyretics (86%) and adrenergic nasal drops/spray (53%); 9% received antibiotics and 3% oseltamivir. Thirty-six percent required at least 1 additional practice visit; 1% was hospitalized. Median absences from childcare were 5 days (IQR, 3-7); parents lost 4 workdays (IQR, 2-6). Symptoms, severity and impact on the family were largely unrelated to (sub)type. However, patients with A(H1N1)pdm09 had fewer underlying conditions (P = 0.017), whereas patients with B more often had pharyngitis (P = 0.022), acute otitis media (P = 0.012) and stenosing laryngotracheitis (P = 0.007).
CONCLUSIONS
Influenza was the most frequently detected viral pathogen in outpatient children with febrile, mostly uncomplicated ARI. In this setting, clinical manifestations and severity were similar across the (sub)types prevalent during the postpandemic seasons.
DOI: 10.1097/INF.0000000000001935
PubMed: 29406467
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Subtype-specific Clinical Presentation, Medical Treatment and Family Impact of Influenza in Children 1-5 Years of Age Treated in Outpatient Practices in Germany During Three Postpandemic Years, 2013-2015.</title><author><name sortKey="Streng, Andrea" sort="Streng, Andrea" uniqKey="Streng A" first="Andrea" last="Streng">Andrea Streng</name><affiliation wicri:level="3"><nlm:affiliation>From the Department of Pediatrics, University Hospital of Würzburg, Würzburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>From the Department of Pediatrics, University Hospital of Würzburg, Würzburg</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Basse-Franconie</region><settlement type="city">Wurtzbourg</settlement></placeName></affiliation></author><author><name sortKey="Prifert, Christiane" sort="Prifert, Christiane" uniqKey="Prifert C" first="Christiane" last="Prifert">Christiane Prifert</name><affiliation wicri:level="3"><nlm:affiliation>Institute of Virology and Immunobiology, University of Würzburg, Würzburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute of Virology and Immunobiology, University of Würzburg, Würzburg</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Basse-Franconie</region><settlement type="city">Wurtzbourg</settlement></placeName></affiliation></author><author><name sortKey="Weissbrich, Benedikt" sort="Weissbrich, Benedikt" uniqKey="Weissbrich B" first="Benedikt" last="Weissbrich">Benedikt Weissbrich</name><affiliation wicri:level="3"><nlm:affiliation>Institute of Virology and Immunobiology, University of Würzburg, Würzburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute of Virology and Immunobiology, University of Würzburg, Würzburg</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Basse-Franconie</region><settlement type="city">Wurtzbourg</settlement></placeName></affiliation></author><author><name sortKey="Sauerbrei, Andreas" sort="Sauerbrei, Andreas" uniqKey="Sauerbrei A" first="Andreas" last="Sauerbrei">Andreas Sauerbrei</name><affiliation wicri:level="1"><nlm:affiliation>Section Experimental Virology, Institute of Medical Microbiology, Jena University Hospital, Jena, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Section Experimental Virology, Institute of Medical Microbiology, Jena University Hospital, Jena</wicri:regionArea><wicri:noRegion>Jena</wicri:noRegion><wicri:noRegion>Jena</wicri:noRegion><wicri:noRegion>Jena</wicri:noRegion></affiliation></author><author><name sortKey="Schmidt Ott, Ruprecht" sort="Schmidt Ott, Ruprecht" uniqKey="Schmidt Ott R" first="Ruprecht" last="Schmidt-Ott">Ruprecht Schmidt-Ott</name><affiliation wicri:level="1"><nlm:affiliation>GSK, Wavre, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>GSK, Wavre</wicri:regionArea><wicri:noRegion>Wavre</wicri:noRegion></affiliation></author><author><name sortKey="Liese, Johannes G" sort="Liese, Johannes G" uniqKey="Liese J" first="Johannes G" last="Liese">Johannes G. Liese</name><affiliation wicri:level="3"><nlm:affiliation>From the Department of Pediatrics, University Hospital of Würzburg, Würzburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>From the Department of Pediatrics, University Hospital of Würzburg, Würzburg</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Basse-Franconie</region><settlement type="city">Wurtzbourg</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29406467</idno><idno type="pmid">29406467</idno><idno type="doi">10.1097/INF.0000000000001935</idno><idno type="wicri:Area/Main/Corpus">000035</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000035</idno><idno type="wicri:Area/Main/Curation">000035</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000035</idno><idno type="wicri:Area/Main/Exploration">000035</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Subtype-specific Clinical Presentation, Medical Treatment and Family Impact of Influenza in Children 1-5 Years of Age Treated in Outpatient Practices in Germany During Three Postpandemic Years, 2013-2015.</title><author><name sortKey="Streng, Andrea" sort="Streng, Andrea" uniqKey="Streng A" first="Andrea" last="Streng">Andrea Streng</name><affiliation wicri:level="3"><nlm:affiliation>From the Department of Pediatrics, University Hospital of Würzburg, Würzburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>From the Department of Pediatrics, University Hospital of Würzburg, Würzburg</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Basse-Franconie</region><settlement type="city">Wurtzbourg</settlement></placeName></affiliation></author><author><name sortKey="Prifert, Christiane" sort="Prifert, Christiane" uniqKey="Prifert C" first="Christiane" last="Prifert">Christiane Prifert</name><affiliation wicri:level="3"><nlm:affiliation>Institute of Virology and Immunobiology, University of Würzburg, Würzburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute of Virology and Immunobiology, University of Würzburg, Würzburg</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Basse-Franconie</region><settlement type="city">Wurtzbourg</settlement></placeName></affiliation></author><author><name sortKey="Weissbrich, Benedikt" sort="Weissbrich, Benedikt" uniqKey="Weissbrich B" first="Benedikt" last="Weissbrich">Benedikt Weissbrich</name><affiliation wicri:level="3"><nlm:affiliation>Institute of Virology and Immunobiology, University of Würzburg, Würzburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute of Virology and Immunobiology, University of Würzburg, Würzburg</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Basse-Franconie</region><settlement type="city">Wurtzbourg</settlement></placeName></affiliation></author><author><name sortKey="Sauerbrei, Andreas" sort="Sauerbrei, Andreas" uniqKey="Sauerbrei A" first="Andreas" last="Sauerbrei">Andreas Sauerbrei</name><affiliation wicri:level="1"><nlm:affiliation>Section Experimental Virology, Institute of Medical Microbiology, Jena University Hospital, Jena, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Section Experimental Virology, Institute of Medical Microbiology, Jena University Hospital, Jena</wicri:regionArea><wicri:noRegion>Jena</wicri:noRegion><wicri:noRegion>Jena</wicri:noRegion><wicri:noRegion>Jena</wicri:noRegion></affiliation></author><author><name sortKey="Schmidt Ott, Ruprecht" sort="Schmidt Ott, Ruprecht" uniqKey="Schmidt Ott R" first="Ruprecht" last="Schmidt-Ott">Ruprecht Schmidt-Ott</name><affiliation wicri:level="1"><nlm:affiliation>GSK, Wavre, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>GSK, Wavre</wicri:regionArea><wicri:noRegion>Wavre</wicri:noRegion></affiliation></author><author><name sortKey="Liese, Johannes G" sort="Liese, Johannes G" uniqKey="Liese J" first="Johannes G" last="Liese">Johannes G. Liese</name><affiliation wicri:level="3"><nlm:affiliation>From the Department of Pediatrics, University Hospital of Würzburg, Würzburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>From the Department of Pediatrics, University Hospital of Würzburg, Würzburg</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Basse-Franconie</region><settlement type="city">Wurtzbourg</settlement></placeName></affiliation></author></analytic><series><title level="j">The Pediatric infectious disease journal</title><idno type="eISSN">1532-0987</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term><term>Bronchitis (drug therapy)</term><term>Bronchitis (virology)</term><term>Child, Preschool</term><term>Epidemiological Monitoring</term><term>Female</term><term>Fever</term><term>Germany (epidemiology)</term><term>Humans</term><term>Infant</term><term>Influenza A Virus, H1N1 Subtype (isolation & purification)</term><term>Influenza A Virus, H3N2 Subtype (isolation & purification)</term><term>Influenza B virus (isolation & purification)</term><term>Influenza, Human (drug therapy)</term><term>Male</term><term>Multiplex Polymerase Chain Reaction</term><term>Oseltamivir (therapeutic use)</term><term>Outpatients (statistics & numerical data)</term><term>Pandemics</term><term>Pharyngitis (drug therapy)</term><term>Pharyngitis (epidemiology)</term><term>Prospective Studies</term><term>Respiratory Tract Infections (drug therapy)</term><term>Respiratory Tract Infections (virology)</term><term>Seasons</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Allemagne (épidémiologie)</term><term>Antiviraux (usage thérapeutique)</term><term>Bronchite (traitement médicamenteux)</term><term>Bronchite (virologie)</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Fièvre</term><term>Grippe humaine (traitement médicamenteux)</term><term>Humains</term><term>Infections de l'appareil respiratoire (traitement médicamenteux)</term><term>Infections de l'appareil respiratoire (virologie)</term><term>Mâle</term><term>Nourrisson</term><term>Oséltamivir (usage thérapeutique)</term><term>Pandémies</term><term>Patients en consultation externe ()</term><term>Pharyngite (traitement médicamenteux)</term><term>Pharyngite (épidémiologie)</term><term>Réaction de polymérisation en chaine multiplex</term><term>Saisons</term><term>Sous-type H1N1 du virus de la grippe A (isolement et purification)</term><term>Sous-type H3N2 du virus de la grippe A (isolement et purification)</term><term>Virus influenza B (isolement et purification)</term><term>Épidémiosurveillance</term><term>Études prospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Oseltamivir</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Germany</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Bronchitis</term><term>Influenza, Human</term><term>Pharyngitis</term><term>Respiratory Tract Infections</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Pharyngitis</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A Virus, H3N2 Subtype</term><term>Influenza B virus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term><term>Sous-type H3N2 du virus de la grippe A</term><term>Virus influenza B</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Outpatients</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Bronchite</term><term>Grippe humaine</term><term>Infections de l'appareil respiratoire</term><term>Pharyngite</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Oséltamivir</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Bronchite</term><term>Infections de l'appareil respiratoire</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Bronchitis</term><term>Respiratory Tract Infections</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Allemagne</term><term>Pharyngite</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Child, Preschool</term><term>Epidemiological Monitoring</term><term>Female</term><term>Fever</term><term>Humans</term><term>Infant</term><term>Male</term><term>Multiplex Polymerase Chain Reaction</term><term>Pandemics</term><term>Prospective Studies</term><term>Seasons</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Fièvre</term><term>Humains</term><term>Mâle</term><term>Nourrisson</term><term>Pandémies</term><term>Patients en consultation externe</term><term>Réaction de polymérisation en chaine multiplex</term><term>Saisons</term><term>Épidémiosurveillance</term><term>Études prospectives</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Limited data on the influenza burden in pediatric outpatients are available, especially regarding direct comparison of the cocirculating (sub)types A(H1N1)pdm09, A(H3N2) and B.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Children 1-5 years of age, unvaccinated against influenza and presenting with febrile acute respiratory infections (ARIs), were enrolled in 33 pediatric practices in Germany from 2013 to 2015 (January-May). Influenza was confirmed by multiplex polymerase chain reaction from pharyngeal swabs and (sub)typed.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>In 805 children with ARI, influenza was the most frequently detected respiratory virus (n = 305; 37.9%). Of 217 influenza patients included, 122 (56.2%) were infected with A(H3N2), 56 (25.8%) with A(H1N1)pdm09 and 39 (18.0%) with B. Median age was 3.7 years [interquartile range (IQR), 2.1-4.8]; 11% had underlying conditions. Median fever duration was 4 days (IQR, 3-5), and the disease duration was 9 days (IQR, 7-12). Most frequent diagnoses were pharyngitis (26%), bronchitis (18%) and acute otitis media (10%). Children received mainly antipyretics (86%) and adrenergic nasal drops/spray (53%); 9% received antibiotics and 3% oseltamivir. Thirty-six percent required at least 1 additional practice visit; 1% was hospitalized. Median absences from childcare were 5 days (IQR, 3-7); parents lost 4 workdays (IQR, 2-6). Symptoms, severity and impact on the family were largely unrelated to (sub)type. However, patients with A(H1N1)pdm09 had fewer underlying conditions (P = 0.017), whereas patients with B more often had pharyngitis (P = 0.022), acute otitis media (P = 0.012) and stenosing laryngotracheitis (P = 0.007).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Influenza was the most frequently detected viral pathogen in outpatient children with febrile, mostly uncomplicated ARI. In this setting, clinical manifestations and severity were similar across the (sub)types prevalent during the postpandemic seasons.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29406467</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1532-0987</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>9</Issue><PubDate><Year>2018</Year><Month>09</Month></PubDate></JournalIssue><Title>The Pediatric infectious disease journal</Title><ISOAbbreviation>Pediatr. Infect. Dis. J.</ISOAbbreviation></Journal><ArticleTitle>Subtype-specific Clinical Presentation, Medical Treatment and Family Impact of Influenza in Children 1-5 Years of Age Treated in Outpatient Practices in Germany During Three Postpandemic Years, 2013-2015.</ArticleTitle><Pagination><MedlinePgn>861-867</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/INF.0000000000001935</ELocationID><Abstract><AbstractText Label="BACKGROUND">Limited data on the influenza burden in pediatric outpatients are available, especially regarding direct comparison of the cocirculating (sub)types A(H1N1)pdm09, A(H3N2) and B.</AbstractText><AbstractText Label="METHODS">Children 1-5 years of age, unvaccinated against influenza and presenting with febrile acute respiratory infections (ARIs), were enrolled in 33 pediatric practices in Germany from 2013 to 2015 (January-May). Influenza was confirmed by multiplex polymerase chain reaction from pharyngeal swabs and (sub)typed.</AbstractText><AbstractText Label="RESULTS">In 805 children with ARI, influenza was the most frequently detected respiratory virus (n = 305; 37.9%). Of 217 influenza patients included, 122 (56.2%) were infected with A(H3N2), 56 (25.8%) with A(H1N1)pdm09 and 39 (18.0%) with B. Median age was 3.7 years [interquartile range (IQR), 2.1-4.8]; 11% had underlying conditions. Median fever duration was 4 days (IQR, 3-5), and the disease duration was 9 days (IQR, 7-12). Most frequent diagnoses were pharyngitis (26%), bronchitis (18%) and acute otitis media (10%). Children received mainly antipyretics (86%) and adrenergic nasal drops/spray (53%); 9% received antibiotics and 3% oseltamivir. Thirty-six percent required at least 1 additional practice visit; 1% was hospitalized. Median absences from childcare were 5 days (IQR, 3-7); parents lost 4 workdays (IQR, 2-6). Symptoms, severity and impact on the family were largely unrelated to (sub)type. However, patients with A(H1N1)pdm09 had fewer underlying conditions (P = 0.017), whereas patients with B more often had pharyngitis (P = 0.022), acute otitis media (P = 0.012) and stenosing laryngotracheitis (P = 0.007).</AbstractText><AbstractText Label="CONCLUSIONS">Influenza was the most frequently detected viral pathogen in outpatient children with febrile, mostly uncomplicated ARI. In this setting, clinical manifestations and severity were similar across the (sub)types prevalent during the postpandemic seasons.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Streng</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Department of Pediatrics, University Hospital of Würzburg, Würzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prifert</LastName><ForeName>Christiane</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Virology and Immunobiology, University of Würzburg, Würzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weissbrich</LastName><ForeName>Benedikt</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Virology and Immunobiology, University of Würzburg, Würzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sauerbrei</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Section Experimental Virology, Institute of Medical Microbiology, Jena University Hospital, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt-Ott</LastName><ForeName>Ruprecht</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>GSK, Wavre, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liese</LastName><ForeName>Johannes G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>From the Department of Pediatrics, University Hospital of Würzburg, Würzburg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pediatr Infect Dis J</MedlineTA><NlmUniqueID>8701858</NlmUniqueID><ISSNLinking>0891-3668</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>20O93L6F9H</RegistryNumber><NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001991" MajorTopicYN="N">Bronchitis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062665" MajorTopicYN="N">Epidemiological Monitoring</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005334" MajorTopicYN="N">Fever</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009981" MajorTopicYN="N">Influenza B virus</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060885" MajorTopicYN="N">Multiplex Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010045" MajorTopicYN="N">Outpatients</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010612" MajorTopicYN="N">Pharyngitis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012141" MajorTopicYN="N">Respiratory Tract Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29406467</ArticleId><ArticleId IdType="doi">10.1097/INF.0000000000001935</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Belgique</li></country><region><li>Bavière</li><li>District de Basse-Franconie</li></region><settlement><li>Wurtzbourg</li></settlement></list><tree><country name="Allemagne"><region name="Bavière"><name sortKey="Streng, Andrea" sort="Streng, Andrea" uniqKey="Streng A" first="Andrea" last="Streng">Andrea Streng</name></region><name sortKey="Liese, Johannes G" sort="Liese, Johannes G" uniqKey="Liese J" first="Johannes G" last="Liese">Johannes G. Liese</name><name sortKey="Prifert, Christiane" sort="Prifert, Christiane" uniqKey="Prifert C" first="Christiane" last="Prifert">Christiane Prifert</name><name sortKey="Sauerbrei, Andreas" sort="Sauerbrei, Andreas" uniqKey="Sauerbrei A" first="Andreas" last="Sauerbrei">Andreas Sauerbrei</name><name sortKey="Weissbrich, Benedikt" sort="Weissbrich, Benedikt" uniqKey="Weissbrich B" first="Benedikt" last="Weissbrich">Benedikt Weissbrich</name></country><country name="Belgique"><noRegion><name sortKey="Schmidt Ott, Ruprecht" sort="Schmidt Ott, Ruprecht" uniqKey="Schmidt Ott R" first="Ruprecht" last="Schmidt-Ott">Ruprecht Schmidt-Ott</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeAllemagneV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000033 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000033 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeAllemagneV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:29406467
|texte= Subtype-specific Clinical Presentation, Medical Treatment and Family Impact of Influenza in Children 1-5 Years of Age Treated in Outpatient Practices in Germany During Three Postpandemic Years, 2013-2015.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:29406467" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV3
| This area was generated with Dilib version V0.6.35. |  |